Skip to main content

Advertisement

Table 5 Efficacy of recent clinical trials with liposomal doxorubicin in mono and combination therapy

From: Nanomedicine review: clinical developments in liposomal applications

ReferencesYearsPhaseDiseaseLFnDose by cycleEfficacy
ORR (%)m-PFS (months)
Banerjee et al. (2018)2018IIROCPLD4840 mg/m2 IV Q4W153.1
Lee et al. (2017)2017IIROCPLD4050 mg/m255
Monk et al. (2017)2017IIROCPLD14940 mg/m221.55.2
Marth et al. (2017)2017IIIROCPLD10950 mg/m2 Q4W217.2
Lindemann et al. (2017)2017IIIROCPLD8640 mg/m216.912.7
Herzog et al. (2016)2016IIROCPLD1550 mg/m2 IV Q4W
Lee et al. (2017)2017IIROCPLD + carboplatin1250 mg/m2 + 5 AUC33.313
Sehouli et al. (2016)2016IIIROCPLD + carboplatin530 mg/m2 + 5 AUC75.111
Nagao et al. (2016)2016IROCPLD + carboplatin + paclitaxel730 mg/m2 + 60 mg/m2 + 6 AUC3312
Landrum et al. (2016)2016IROCPLD + carboplatin + veliparib1030 mg/m2 + 5 AUC + 50 mg50
Kim et al. (2015)2016IROCPLD + carboplatin + farletuzumab1530 mg/m2 + 5–6 AUC + 2.5 mg/kg73.210.4b
Runnebaum et al. (2018)2018IIROCPLD + trabectedin7730 mg/m2 + 1.1 mg/m2 IV Q3W316.3
Monk et al. (2017)2017IIROCPLD + motolimod14840 mg/m2 + 30 mg/m220.94.8
Marth et al. (2017)2017IIIROCPLD + trebananib11450 mg/m2 Q4W + 15 mg/kg Q1W467.6
Shoji et al. (2017)2017IIROCPLD + irinotecan3130 mg/m232.32
Thaker et al. (2017)2017IROCPLD + GEN750 mg/m2 + 36 mg/m2294.7
Herzog et al. (2016)2016IIROCPLD + vintafolide2250 mg/m2 IV Q4W + 7.5 mg IV Q2W
Jehn et al. (2016)2016IIMBCCaelix®2525 mg/m24.51.75a
Harbeck et al. (2016)2016IIIMBCPLD105150 mg/m26a
Chang et al. (2018)2018IIMBCPLD + CPM2130 mg/m2 Q4–6W + 60 mg/m2 PO daily216.4
Tampaki et al. (2018)2018IIBCPLD + CPM + bevacizumab + paclitaxel6230 mg/m2 + 600 mg/m2 + 8 mg/kg + 120 mg/m2 Q2W95.2
Basho et al. (2016)2016ITNBCPLD + bevacizumab + temsirolimus2430 mg/m2 + 15 mg/kg Q3W + 25 mg Q1W IV214
PLD + bevacizumab + everolimus930 mg/m2 + 15 mg/kg Q3W IV + 7.5 mg PO daily
Rocca et al. (2017)2017IBCPLD + lapatinib930 mg/m2 Q3W + 1500 mg/day on days 1–21115.75a
Coltelli et al. (2017)b2017IIBCMyocet® + CPM + paclitaxel4760 mg/m2 + 600 mg/m2 IV Q3W + 80 mg/m2 Q1W
Orlowski et al. (2016)2016IIIRMMPLD + bortezomib32430 mg/m2 + 1.3 mg/m233.0c
Cohen et al. (2018)2018IIMMPLD + pomalidomide + dexamethasone165 mg/m2 + 40 mg IV days 1, 4, 8 and 11 + 4 mg/day for 21 days, 28-day cycle315
Becker et al. (2016)2016IIMMPLD + bortezomib + CPM + dexamethasone2030 mg/m2 IV Q4W + 1.6 mg/m2 + 300 mg/m2 + 40 mg three times by cycle90
Voorhees et al. (2017)2017IRMMPLD + bortezomib + vorinostat3230 mg/m2 + 1.3 mg/m2 + escalating dose of vorinostat6513.9
Casadei et al. (2018)2018IMHLPLD960 mg IV Q3W50
Luminari et al. (2017)2017IIDLBCLMyocet® + CPM + vincristine + prednisone + rituximab4950 mg/m2 + 750 mg/m2 and 1.4 mg/m2 day 1 + 100 mg days 1–5 + 375 mg/m2 day 3 of each cycle7217
Fridrik et al. (2016)2016IIDLBCLMyocet® + CPM + vincristine + prednisolone + rituximab4050 mg/m2 + 750 mg/m2 + 1.4 mg/m2 + 40 mg/m2/day for 5 days + 375 mg IV QW397.5
  1. LF liposomal formulation, ORR objective response rate, m-PFS median progression-free survival, CPM cyclophosphamide, PLD PEGylated liposomal doxorubicin,GEN an IL-12 plasmid formulated with PEG–PEI–cholesterol lipopolymer; Q4W, Q3W, Q2W, Q1W, every 4, 3, 2 and 1 weeks, respectively, AUC areas under curve, ROC recurrent ovarian cancer, MBC metastatic breast cancer, BC breast cancer, TNBC triple-negative breast cancer, RMM relapse or refractory multiple myeloma, MM multiple myeloma, MHL multirelapsed Hodgkin’s lymphoma, DLBCL diffuse large B-cell lymphoma
  2. aTTP, time to progression [the event of interest is only disease progression, while patients who die of other causes are not included (Fiteni et al. 2014)]
  3. bMedian radiologic PFS
  4. cMedian overall survival. The median follow-up for survival was 103 months (8.6 years)